These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631 [TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Wong CR; Nguyen MH; Lim JK World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736 [TBL] [Abstract][Full Text] [Related]
11. Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease". Jamialahmadi O; Bianco C; Pelusi S; Romeo S; Valenti L J Hepatol; 2021 Jun; 74(6):1494-1496. PubMed ID: 33676949 [No Abstract] [Full Text] [Related]
12. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease. Seif El Dahan K; Daher D; Singal AG Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899 [TBL] [Abstract][Full Text] [Related]
13. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208 [TBL] [Abstract][Full Text] [Related]
14. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Cernea S; Onișor D World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124 [TBL] [Abstract][Full Text] [Related]
15. Clinical features and management issues of NAFLD-related HCC: what we know so far. Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057 [TBL] [Abstract][Full Text] [Related]
16. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Degasperi E; Colombo M Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072 [TBL] [Abstract][Full Text] [Related]
17. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Margini C; Dufour JF Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627 [TBL] [Abstract][Full Text] [Related]
18. NAFLD-related hepatocellular carcinoma: The growing challenge. Shah PA; Patil R; Harrison SA Hepatology; 2023 Jan; 77(1):323-338. PubMed ID: 35478412 [TBL] [Abstract][Full Text] [Related]
19. Should Patients With NAFLD/NASH Be Surveyed for HCC? Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818 [TBL] [Abstract][Full Text] [Related]
20. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies. Chen J; Song S; Li X; Bian D; Wu X Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]